#	Pagina
attuale pagina	/open-h2020/projects/203214/index.html

Opendata, web and dolomites

PET3D SIGNED

PET Imaging in Drug Design and Development

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

PET3D project word cloud

Explore the words cloud of the PET3D project. It provides you a very rough idea of what is the project "PET3D" about.

cycle pursued center innovation clinical nervous strategy pharmaceutical molecular scientists changing representing landscape lack positron stage paradigm edge terminus etn sustainable effective central obstacle beneficiary efficient cardiovascular questions therapeutic emission latter transition play drug ideally shaping suitably health render cutting capacity training treatment earlier accurately unsustainable company site inefficient suited care answers 15 profile affordable keep tomography translational manner gap pet3d fundamental drugs pivotal rationalized therapy oncology disease dramatic big esrs academic pet imaging answering trained chemistry personalized industry worldwide fill quality radiochemistry generation

Project "PET3D" data sheet

The following table provides information about the project.

Coordinator	LOUGHBOROUGH UNIVERSITY Organization address address: ASHBY ROAD city: LOUGHBOROUGH postcode: LE11 3TU website: www.lboro.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	http://www.pet3d.eu/
Total cost	3˙912˙634 €
EC max contribution	3˙901˙247 € (100%)
Programme	1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
Code Call	H2020-MSCA-ITN-2015
Funding Scheme	MSCA-ITN-ETN
Starting year	2016
Duration (year-month-day)	from 2016-06-01 to 2020-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	LOUGHBOROUGH UNIVERSITY LOUGHBOROUGH UNIVERSITY Organization address address: ASHBY ROAD city: LOUGHBOROUGH postcode: LE11 3TU website: www.lboro.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LOUGHBOROUGH)	coordinator	165˙187.00
2	THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN Organization address address: KING'S COLLEGE REGENT WALK city: ABERDEEN postcode: AB24 3FX website: http://www.abdn.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (ABERDEEN)	participant	620˙515.00
3	UNIVERSITETET I BERGEN UNIVERSITETET I BERGEN Organization address address: MUSEPLASSEN 1 city: BERGEN postcode: 5020 website: www.uib.no contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (BERGEN)	participant	572˙550.00
4	STICHTING VUMC STICHTING VUMC Organization address address: DE BOELELAAN 1117 city: AMSTERDAM postcode: 1081 HV website: www.vumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	510˙748.00
5	VRIJE UNIVERSITEIT BRUSSEL VRIJE UNIVERSITEIT BRUSSEL Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 website: www.vub.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUSSEL)	participant	501˙120.00
6	WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER Organization address address: SCHLOSSPLATZ 2 city: MUENSTER postcode: 48149 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENSTER)	participant	498˙432.00
7	ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE Organization address address: PASEO MIRAMON 182, PARQUE TECNOLOGICO DE SAN SEBASTIAN EDIFICIO EMPRESARIAL C city: SAN SEBASTIAN postcode: 20009 website: www.cicbiomagune.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (SAN SEBASTIAN)	participant	495˙745.00
8	IMANOVA LIMITED IMANOVA LIMITED Organization address address: BURLINGTON DANES BUILDING, IMPERIAL COLLEGE LONDON HAMMERSMITH HOSPITAL, DU CANE ROAD city: LONDON postcode: W12 0NN website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	273˙287.00
9	ASTRAZENECA AB ASTRAZENECA AB Organization address address: Vastra Maelarhamnen city: SODERTAELJE postcode: 151 85 website: www.astrazeneca.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (SODERTAELJE)	participant	263˙659.00
10	STICHTING VU STICHTING VU Organization address address: DE BOELELAAN 1105 city: AMSTERDAM postcode: 1081 HV website: www.vu.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	0.00

Map

Project objective

The drug development strategy currently pursued by the pharmaceutical industry worldwide is inefficient and unsustainable for the health care system. To keep the latter affordable, drug development should become more efficient and drug treatment should become more “personalized” and “rationalized”. Molecular imaging can play a pivotal role in changing the landscape of drug design/development and improving the health care system. Positron Emission Tomography (PET) imaging, in particular, is the technology that has the potential to lead this fundamental innovation by providing at a much earlier stage reliable answers to key questions emerging during the care cycle: what and where is the disease? Is the disease accurately targeted by the therapy? Is the treatment effective? By answering the questions above, PET imaging has the capacity to render much more effectively the transition from pre-clinical to clinical phase, and to strongly facilitate the development of better drugs at an earlier stage and in a much more sustainable manner. The main obstacle to this change of paradigm in drug design and development is the lack of suitably trained translational scientists directly involved in PET imaging and imaging scientists with high-profile training in chemistry and PET-radiochemistry, which is particularly dramatic in Europe. This consortium is ideally suited to fill this gap, by providing top-quality training to the next generation of translational PET imaging scientists who will play a key role in shaping the future of drug design and development. The PET3D ETN will focus on 15 cutting-edge research projects in the 3 main therapeutic areas (oncology, cardiovascular, central nervous system) that will be conducted by 15 ESRs at 8 European beneficiary Institutions, 6 academic (all having a PET center on site) and 2 non-academic (one with a PET center on site and one big pharmaceutical company) representing the drug design and development terminus of the project.

Deliverables

List of deliverables.
Award of PhD degree to ESR15	Documents, reports	2020-03-06 15:37:29
PET3D website	Websites, patent fillings, videos etc.	2019-08-30 14:12:01

Take a look to the deliverables list in detail: detailed list of PET3D deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Bastian Zinnhardt, Maximilian Wiesmann, Lisa Honold, Cristina Barca, Michael SchÃ¤fers, Amanda J Kiliaan, Andreas H Jacobs In vivo imaging biomarkers of neuroinflammation in the development and assessment of stroke therapies - towards clinical translation published pages: 2603-2620, ISSN: 1838-7640, DOI: 10.7150/thno.24128	Theranostics 8/10	2019-08-30
2018	Ryan A. Bragg, Malvika Sardana, Markus Artelsmair, Charles S. Elmore New trends and applications in carboxylation for isotope chemistry published pages: , ISSN: 0362-4803, DOI: 10.1002/jlcr.3633	Journal of Labelled Compounds and Radiopharmaceuticals	2019-08-30
2019	Markus Artelsmair, Patricia Miranda-Azpiazu, Lee Kingston, Jonas Bergare, Magnus Schou, Andrea Varrone, Charles S. Elmore Synthesis, 3 H-labelling and in vitro evaluation of a substituted dipiperidine alcohol as a potential ligand for chemokine receptor 2 published pages: , ISSN: 0362-4803, DOI: 10.1002/jlcr.3731	Journal of Labelled Compounds and Radiopharmaceuticals	2019-08-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PET3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PET3D" are provided by the European Opendata Portal: CORDIS opendata.